Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression.

L C Dormegny-JeanjeanO A E MainbergerC de Crespin de BillyA ObrechtV DanilaA ErbH M ArcayS WeibelF BlancG MeyerM TomsaG BertschyF DuvalJ R Foucher

Published in: L'Encephale (2023)

There was no life-threatening safety issue in combining MAOI and D2/3r-dAG, especially regarding cardiovascular side effects. The systematic screening of AE might account for their frequency, but these precluded the treatment in only two patients. Comparative studies are needed to assess the efficacy of this new combination.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
depressive symptoms
patient reported outcomes
case control
patient reported